TCL Archive Also Senate, House committees request further research, reports from NCI. September 19, 2003
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive AACI Asks NCI for Better Definitions Of Center Types, Development Of Objectives, Priorities June 25, 1976